Turbine announced a collaboration with AstraZeneca (AZN) to test the ability of Turbine’s platform to rationalize antibody-drug conjugate discovery by predicting response mechanisms, informing ADC positioning, and reducing the need for large-scale cell line screens. This collaboration will apply Turbine’s platform, which virtualizes biological experiments at scale, to not only improve the efficiency and speed of ADC discovery but also deliver mechanistic insights that current experimental screening approaches may typically lack.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s CKD Study in Brazil: Key Insights and Market Impact
- AstraZeneca’s Olaparib Safety Study: Key Insights for Investors
- AstraZeneca’s AZD4144: Promising Obesity Treatment Under Study
- AstraZeneca’s Innovation and Strategic Positioning Reinforce Buy Rating Amidst TROPION-Breast02 Success
- AstraZeneca reports baxdrostat met primary endpoint in Bax24 trial